News – Page 1148 – Endpoints News

Allergan bags two new deals, takes option to buy Lysosomal Therapeutics and pays $50M for microbiome pact

9 years ago

Takeda grabs Ariad, expands oncology portfolio in $5.2B buyout

9 years ago

Celgene antes up $55M, grabs option to buy the autoimmune upstart Anokion

9 years ago

Savara jumping to the NYSE in reverse merger with zombie biotech Mast

9 years ago

The forecast for biotech IPOs in 2017? Not nearly as hot as the industry would like

9 years ago

Getting to work on pipeline construction, new Ipsen CEO forges $1B deal to buy Merrimack’s struggling Onivyde

9 years ago

Genentech vet Troy Cox named Foundation Med CEO; Momenta inks a $600M collaboration deal

9 years ago

2017 gets started with a bang as we get a glimpse of the good, the bad and the ugly

9 years ago

Eli Lilly, Novartis back a $26M round for Cavion’s work on neurological diseases

9 years ago

Ex-Biogen chief George Scangos to spearhead a Gates-backed startup with big plans to fight infectious diseases

9 years ago

Novartis adds to its cardio pipeline with $1.65B Ionis pact

9 years ago

Analysts assess the damage — and next steps — after Regeneron/Sanofi get slammed in court

9 years ago

Gilead tosses $100M milestone chip in its fast-growing gamble on new NASH drugs

9 years ago

Pieris soars on $31M-plus checkpoint development deal; Luca Santarelli takes helm at Therachon

9 years ago

An upstart jumps almost overnight from preclinical to PhI with a $35M Takeda deal and a buyout option

9 years ago

J&J grabs an option to buy a NASH drug in latest string of biotech deals

9 years ago

Another Langer-backed biotech breaks out of stealth mode, aims for the clinic with hearing loss therapy

9 years ago

Neon Therapeutics bags a $70M round for early-stage neoantigen research

9 years ago

Aeterna Zentaris doubles down on macimorelin PhIII, and loses

9 years ago

Arena sheds ties to weight drug Belviq, completing a makeover

9 years ago

Former Novartis pharmaceuticals chief David Epstein is going biotech

9 years ago

scPharmacuticals raises $45M B round; Struggling Nivalis and Acura take stock of “strategic alternatives”

9 years ago

M&A inflation just pushed the average biopharma valuation to a scary new peak

9 years ago

Julian Adams jumps ship from a deeply troubled Infinity Pharma

9 years ago

First page Previous page 1145 1146 114711481149 1150 1151 Next page Last page